Q3A(R) Impurities in New Drug Substances
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
June 6, 2008
April 8, 2020
7e49ddae-0c3a-43e8-9c8a-ae972f01bd2b
Related Documents
E15 Pharmacogenomics Definitions and Sample Coding
Guidance DocumentApril 8, 2008Center for Drug Evaluation and Research
S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals
Guidance DocumentSeptember 17, 2008Center for Drug Evaluation and Research
Q10 Pharmaceutical Quality System
Guidance DocumentApril 8, 2009Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.